Western Union Continues to Connect Communities and Economies at a Critical Time
25.6.2020 15:00:00 EEST | Business Wire | Press release
Western Union (NYSE: WU), a global leader in cross-border, cross-currency money movement and payments, today released its second annual Environmental, Social and Governance (ESG) Report, which spotlights the Company’s 2019 ESG progress. The report also highlights Western Union’s response and ongoing initiatives surrounding the COVID-19 pandemic and social justice movements across the globe in early 2020.
“Today, against the backdrop of COVID-19 and global protests against social injustice, business’s role in building a more united future has never seemed more relevant – or more urgent. Serving our stakeholders in today’s world takes determination and innovation. It demands that we build unity through ingenuity to create new, lasting solutions for people, businesses, and societies,” said Hikmet Ersek, President and CEO, Western Union. “This report provides an update on Western Union’s ESG efforts, and how we are addressing some of the most pressing global issues facing society, our shared environment, and our Company.”
The report highlights six key areas where Western Union is making an impact globally:
Connecting people and businesses to the global economy: Our services connect people and businesses pursuing global opportunities – for example, individuals looking to better the lives of their families, and businesses looking for new partners, customers, and markets. The transactions we process build bridges across economies, geographies, and cultures.
- In response to COVID-19, Western Union doubled down on its commitment to serve customers with a range of new offerings and resources including piloting home delivery of money transfers, introducing “digital location” concierge services to offer personalized phone or video support to help customers make digital money transfers, expanding westernunion.com to five additional countries bringing the total to more than 75, and expanding real-time account and wallet payout to 50 countries.
Fostering an engaging and inclusive workplace: Western Union works to build and support a workforce that reflects the global diversity of the 150 million customers we serve in more than 200 countries and territories around the world. It starts at the most senior levels of our business and manifests itself throughout our Board of Directors and our global workforce. We are actively engaging in open and honest dialogue with our employees and we are committed to playing a role in the fight for positive change globally. 2019 highlights include:
- Reaching gender parity with our customers and employees: approximately half of our customers and half of our global workforce are women.
- Our executive team in 2019 was comprised of 40% women and includes leaders born in 10 different countries who have wide-ranging global leadership experience.
Moving money with integrity: We are committed to using the right combination of people and technology to protect our customers and partners, keep illicit activity out of our network, and ensure we conduct our business with integrity.
- In 2019, we prevented $1.1 billion in fraudulent transactions. Overall industry data suggests a growing rate of fraudulent activity. Western Union’s fraud levels, however, are trending downward.
- Our Financial Intelligence Unit continues to partner with law enforcement and nonprofit entities to better target and disrupt human trafficking financial flows. This team has conducted approximately 1,800 human trafficking investigations since 2013, resulting in hundreds of arrests and the rescue of hundreds of victims.
Governing and managing for success: Western Union’s governance structures and practices provide oversight and guidance around critical issues, including ethics, board diversity, executive compensation, fair competition, data privacy, and cybersecurity, and board diversity. 2019 highlights include:
- Our Board is comprised of a wide range of nationalities from around the world.
- Three of our 11 Board members were women.
Safeguarding our shared environment: We are committed to acting responsibly to respect the environment and minimize our footprint.
- 25% of building materials, by value, are made of recycled materials at our global headquarters.
- We have equipped our major offices with state-of-the-art video conferencing technology, which reduced the need for air travel between locations, even prior to COVID-19.
Catalyzing change through the Western Union Foundation: The Western Union Foundation works to provide vulnerable youth with the skills needed to succeed in today’s global digital economy, and to support people across the globe through humanitarian relief.
- In 2019, the Western Union Foundation launched Opportunity Beyond Borders, a three-year and $15-million commitment to provide vulnerable youth with the skills and training needed to succeed in today’s global digital economy.
- As the impact of COVID-19 spread across the globe, Western Union and the Western Union Foundation announced a global matching challenge, with a total commitment of $1.3 million in customer, corporate, employee, and agent donations towards the global fight against the virus.
The Western Union 2019 ESG Report is available at: http://ir.westernunion.com/investor-relations/ESG/default.aspx. It is prepared in accordance with the Global Reporting Initiative (GRI) standards, and also includes responses to select relevant metrics from the Sustainability Accounting Standards Board (SASB) Standards.
WU-G
About Western Union
The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Our omnichannel platform connects the digital and physical worlds and makes it possible for consumers and businesses to send and receive money and make payments with speed, ease, and reliability. As of March 31, 2020, our network included over 550,000 retail agent locations offering our branded services in more than 200 countries and territories, with the capability to send money to billions of accounts. Additionally, westernunion.com, our fastest growing channel in 2019, is available in over 75 countries, plus additional territories, to move money around the world. With our global reach, Western Union moves money for better, connecting family, friends, and businesses to enable financial inclusion and support economic growth. For more information, visit www.westernunion.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005415/en/
Contact information
Western Union Contacts
Investor Relations:
Brendan Metrano; Brendan.metrano@wu.com
+1(720) 332-8089
Media Relations:
Western Union Global Communications
Rachel Rogala; Rachel.Rogala@wu.com
+ 1 (303) 808-2674
Pia De Lima; Pia.DeLima@wu.com
+1 (954) 260-5732
Western Union Americas
Margaret Fogarty; Margaret.Fogarty@wu.com
Western Union Middle East & Africa
Mohamed El Khalouki; Mohamed.ElKhalouki@wu.com
Western Union Asia-Pacific
Karen Santos; Karen.Santos2@wu.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release
Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release
Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release
Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
